MedDataX Logo

MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)

NCT ID: NCT05007106

Last Updated: 2025-08-14

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

613 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-09-16

Study Completion Date

2025-08-05

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine the safety, tolerability, and preliminary efficacy of pembrolizumab/vibostolimab co-formulation (MK-7684A) with or without other anticancer therapies in participants with selected advanced solid tumors. The primary hypothesis is that pembrolizumab/vibostolimab co-formulation is superior to pembrolizumab alone in terms of objective response rate or progression-free survival in participants with cervical cancer.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-012/KEYNOTE-012)

NCT01848834

Cancer Solid Tumor
COMPLETED PHASE1

A Study to Evaluate the Bioavailability of Pembrolizumab (MK-3475) Via Subcutaneous (SC) Injection of Pembrolizumab Formulated With Berahyaluronidase Alfa (MK-5180) [MK-3475A] In Advanced Solid Tumors (MK-3475A-C18)

NCT05017012

Advanced or Metastatic Solid Tumors
ACTIVE_NOT_RECRUITING PHASE1

A Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors

NCT06764771

Advanced Malignant Tumors
ACTIVE_NOT_RECRUITING PHASE1

Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs. Placebo Plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (MK-3475-355/KEYNOTE-355)

NCT02819518

Triple Negative Breast Cancer (TNBC)
COMPLETED PHASE3

Pembrolizumab and Chemotherapy Treatment or no Treatment Guided by the Level of TILs in Resected Early-stage TNBC

NCT06078384

Triple-negative Breast Cancer
RECRUITING PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Uterine Cervical Neoplasms Endometrial Neoplasms Squamous Cell Carcinoma of Head and Neck Gallbladder Neoplasms Cholangiocarcinoma Esophageal Neoplasms Triple Negative Breast Neoplasms Hepatocellular Carcinoma Urinary Bladder Neoplasms Ovarian Neoplasms Stomach Neoplasms

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Participants with locally recurrent unresectable or metastatic cervical cancer whose tumors express programmed cell death 1 ligand 1 (PD-LI) and have a combined positive score (CPS) ≥1 will be randomly assigned to treatment with either pembrolizumab/vibostolimab co-formulation or pembrolizumab only. The other study intervention arms will be assigned to participants depending on the selected cancer type.
Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Pembrolizumab/Vibostolimab Co-Formulation

Participants receive pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via intravenous (IV) infusion every 3 weeks (Q3W) up to 35 cycles. Participants receiving pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) will be given the option to transition to pembrolizumab monotherapy.

Group Type EXPERIMENTAL

Pembrolizumab/Vibostolimab Co-Formulation

Intervention Type BIOLOGICAL

Pembrolizumab 200 mg plus vibostolimab 200 mg administered via IV infusion Q3W

Pembrolizumab

Intervention Type BIOLOGICAL

Pembrolizumab 200 mg administered via IV infusion Q3W.

Pembrolizumab

Participants receive pembrolizumab 200 mg via IV infusion Q3W up to 35 cycles.

Group Type EXPERIMENTAL

Pembrolizumab

Intervention Type BIOLOGICAL

Pembrolizumab 200 mg administered via IV infusion Q3W.

Pembrolizumab/Vibostolimab Co-Formulation + Lenvatinib (Endometrial Cancer Cohort)

Participants receive pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via intravenous IV infusion Q3W up to 35 cycles, plus lenvatinib 20 mg once daily (qd) up to 45 cycles. Participants receiving pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) will be given the option to transition to pembrolizumab monotherapy in combination with Lenvatinib.

Group Type EXPERIMENTAL

Pembrolizumab/Vibostolimab Co-Formulation

Intervention Type BIOLOGICAL

Pembrolizumab 200 mg plus vibostolimab 200 mg administered via IV infusion Q3W

Pembrolizumab

Intervention Type BIOLOGICAL

Pembrolizumab 200 mg administered via IV infusion Q3W.

Lenvatinib

Intervention Type DRUG

Lenvatinib 20 mg, 12 mg, or 8 mg (dependent on cancer type and body weight) administered via oral capsule QD

Pembrolizumab/Vibostolimab Co-Formulation + Lenvatinib (Hepatocellular Cancer Cohort)

Participants receive pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via intravenous IV infusion Q3W up to 35 cycles, plus lenvatinib 12 mg (body weight \[BW\] ≥60 kg) or lenvatinib 8 mg (BW \<60 kg) qd up to 45 cycles. Participants receiving pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) will be given the option to transition to pembrolizumab monotherapy in combination with Lenvatinib.

Group Type EXPERIMENTAL

Pembrolizumab/Vibostolimab Co-Formulation

Intervention Type BIOLOGICAL

Pembrolizumab 200 mg plus vibostolimab 200 mg administered via IV infusion Q3W

Pembrolizumab

Intervention Type BIOLOGICAL

Pembrolizumab 200 mg administered via IV infusion Q3W.

Lenvatinib

Intervention Type DRUG

Lenvatinib 20 mg, 12 mg, or 8 mg (dependent on cancer type and body weight) administered via oral capsule QD

Pembrolizumab/Vibostolimab + 5-Fluorouracil + Cisplatin

Participants receive pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via IV infusion Q3W, plus 5-fluorouracil (5-FU), plus Cisplatin as background therapy. Participants receiving pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) will be given the option to transition to pembrolizumab monotherapy in combination with 5-Fluorouracil + Cisplatin.

Group Type EXPERIMENTAL

Pembrolizumab/Vibostolimab Co-Formulation

Intervention Type BIOLOGICAL

Pembrolizumab 200 mg plus vibostolimab 200 mg administered via IV infusion Q3W

Pembrolizumab

Intervention Type BIOLOGICAL

Pembrolizumab 200 mg administered via IV infusion Q3W.

5-Fluorouracil

Intervention Type DRUG

5-FU 800 mg/m\^2/day administered via continuous IV infusion on each of days 1 to 5 Q3W for up to 35 cycles

Cisplatin

Intervention Type DRUG

Cisplatin administered via IV infusion

Pembrolizumab/Vibostolimab Co-Formulation + Paclitaxel

Participants receive pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via IV infusion Q3W up to 35 cycles, plus paclitaxel as background therapy until meeting discontinuation criteria. Participants receiving pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) will be given the option to transition to pembrolizumab monotherapy in combination with Paclitaxel.

Group Type EXPERIMENTAL

Pembrolizumab/Vibostolimab Co-Formulation

Intervention Type BIOLOGICAL

Pembrolizumab 200 mg plus vibostolimab 200 mg administered via IV infusion Q3W

Pembrolizumab

Intervention Type BIOLOGICAL

Pembrolizumab 200 mg administered via IV infusion Q3W.

Paclitaxel

Intervention Type DRUG

Paclitaxel administered via IV infusion at investigator's choice of dose

Pembrolizumab/Vibostolimab Co-Formulation + Gemcitabine/Cisplatin

Participants receive pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via IV infusion Q3W up to 35 cycles, plus gemcitabine (until disease progression or unacceptable toxicity) and cisplatin (up to 8 cycles) as background therapy. Participants receiving pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) will be given the option to transition to pembrolizumab monotherapy in combination with Gemcitabine/Cisplatin

Group Type EXPERIMENTAL

Pembrolizumab

Intervention Type BIOLOGICAL

Pembrolizumab 200 mg administered via IV infusion Q3W.

Cisplatin

Intervention Type DRUG

Cisplatin administered via IV infusion

Gemcitabine

Intervention Type DRUG

Gemcitabine administered via IV infusion on Day 1 and Day 8 of each 3-week cycle, until PD or unacceptable toxicity

Pembrolizumab/Vibostolimab Co-Formulation+ Carboplatin/Paclitaxel/Bevacizumab

Participants receive pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via IV infusion Q3W up to 35 cycles, plus carboplatin, paclitaxel, and bevacizumab as local standard of care (SOC) background therapy. Participants receiving pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) will be given the option to transition to pembrolizumab monotherapy in combination with Carboplatin/Paclitaxel/Bevacizumab.

Group Type EXPERIMENTAL

Pembrolizumab

Intervention Type BIOLOGICAL

Pembrolizumab 200 mg administered via IV infusion Q3W.

Paclitaxel

Intervention Type DRUG

Paclitaxel administered via IV infusion at investigator's choice of dose

Carboplatin

Intervention Type DRUG

Carboplatin administered via IV infusion at investigator's choice of dose and frequency

Docetaxel

Intervention Type DRUG

For participants who cannot receive paclitaxel due to hypersensitivity or adverse event (AE), docetaxel administered via IV infusion Q3W, Day 1 of each cycle for up to 5 cycles

Bevacizumab

Intervention Type DRUG

Bevacizumab (or biosimilars such as MVASI®, Zirabev®, Aybintio®, ALYMSYS®, Abevmy®, Onbevezy®, Vegzelma®) administered via IV infusion Q3W; Day 1 of each 3-week cycle for up to 15 cycles

Pembrolizumab/Vibostolimab Co-Formulation + Capecitabine/Oxaliplatin

Participants receive pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via IV infusion Q3W up to 35 cycles, plus capecitabine and oxaliplatin as background therapy. Participants receiving pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) will be given the option to transition to pembrolizumab monotherapy in combination with Capecitabine/Oxaliplatin.

Group Type EXPERIMENTAL

Pembrolizumab

Intervention Type BIOLOGICAL

Pembrolizumab 200 mg administered via IV infusion Q3W.

Capecitabine

Intervention Type DRUG

Capecitabine administered via oral tablet twice daily on Days 1 to 14 of each cycle (Q3W) for up to 35 cycles

Oxaliplatin

Intervention Type DRUG

Oxaliplatin administered via IV infusion Q3W up to 35 cycles

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Pembrolizumab/Vibostolimab Co-Formulation

Pembrolizumab 200 mg plus vibostolimab 200 mg administered via IV infusion Q3W

Intervention Type BIOLOGICAL

Pembrolizumab

Pembrolizumab 200 mg administered via IV infusion Q3W.

Intervention Type BIOLOGICAL

Lenvatinib

Lenvatinib 20 mg, 12 mg, or 8 mg (dependent on cancer type and body weight) administered via oral capsule QD

Intervention Type DRUG

5-Fluorouracil

5-FU 800 mg/m\^2/day administered via continuous IV infusion on each of days 1 to 5 Q3W for up to 35 cycles

Intervention Type DRUG

Cisplatin

Cisplatin administered via IV infusion

Intervention Type DRUG

Paclitaxel

Paclitaxel administered via IV infusion at investigator's choice of dose

Intervention Type DRUG

Gemcitabine

Gemcitabine administered via IV infusion on Day 1 and Day 8 of each 3-week cycle, until PD or unacceptable toxicity

Intervention Type DRUG

Carboplatin

Carboplatin administered via IV infusion at investigator's choice of dose and frequency

Intervention Type DRUG

Docetaxel

For participants who cannot receive paclitaxel due to hypersensitivity or adverse event (AE), docetaxel administered via IV infusion Q3W, Day 1 of each cycle for up to 5 cycles

Intervention Type DRUG

Bevacizumab

Bevacizumab (or biosimilars such as MVASI®, Zirabev®, Aybintio®, ALYMSYS®, Abevmy®, Onbevezy®, Vegzelma®) administered via IV infusion Q3W; Day 1 of each 3-week cycle for up to 15 cycles

Intervention Type DRUG

Capecitabine

Capecitabine administered via oral tablet twice daily on Days 1 to 14 of each cycle (Q3W) for up to 35 cycles

Intervention Type DRUG

Oxaliplatin

Oxaliplatin administered via IV infusion Q3W up to 35 cycles

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

MK-7684A MK-3475 KEYTRUDA® Lenvima E7080 MK-7902 5-FU Fluracil Platinol cis Platinum Taxol Abraxane Anzatax

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* One of the following histologically or cytologically confirmed, advanced (unresectable or metastatic) solid tumors:

* Squamous cell carcinoma, adenosquamous carcinoma, or adenocarcinoma of the cervix
* Endometrial cancer
* Head and neck squamous cell carcinoma (HNSCC)
* Unresectable biliary adenocarcinoma (gallbladder or biliary tree \[intrahepatic or extrahepatic\] cholangiocarcinoma)
* Adenocarcinoma or squamous cell carcinoma of the esophagus or advanced/metastatic Siewert type 1 adenocarcinoma of the gastroesophageal junction (GEJ).
* Triple-negative breast cancer (TNBC)
* Hepatocellular carcinoma (HCC)
* Urothelial carcinoma of the renal pelvis, ureter, bladder, or urethra
* Ovarian cancer
* Gastric cancer
* Measurable disease per RECIST v1.1 as assessed by BICR or local site investigator.
* Adequately controlled blood pressure (BP) with or without antihypertensive medications.
* Human immunodeficiency virus (HIV)-infected participants must have well controlled HIV on anti-retroviral therapy (ART).
* Male participants must agree to follow contraceptive guidance.
* Female participants are not pregnant or breastfeeding, not a woman of child-bearing potential (WOCBP) or is a WOCBP and agrees to follow contraceptive guidance.
* Adequate organ function.

Exclusion Criteria

* History of a second malignancy, unless potentially curative treatment has been completed with no evidence of malignancy for 3 years.
* Prior therapy with anti-programmed cell-death (PD-1), anti-PD-L1, anti-PD-L2, or anti-T-cell immunoreceptor with Ig and ITIM domains (TIGIT) agent.
* Prior systemic anticancer therapy including investigational agents within 4 weeks before randomization/allocation.
* Received a live or live-attenuated vaccine within 30 days before the first dose of study intervention. Administration of killed vaccines are allowed.
* Diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy or any other form of immunosuppressive therapy within 7 days before the first dose of study medication.
* Active autoimmune disease that has required systemic treatment in past 2 years.
* Active infection requiring systemic therapy.
* Concurrent active hepatitis B and hepatitis C virus infection.
* History of allogenic tissue/solid organ transplant.
* Previous treatment with lenvatinib (for participants who will receive lenvatinib in their assigned treatment arm).
* Has clinically significant cardiovascular disease within 12 months from first dose of study intervention.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Merck Sharp & Dohme LLC

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Medical Director

Role: STUDY_DIRECTOR

Merck Sharp & Dohme LLC

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Alaska Womens Cancer Care ( Site 1016)

Anchorage, Alaska, United States

Site Status

City of Hope Comprehensive Cancer Center ( Site 1001)

Duarte, California, United States

Site Status

University of California, Irvine (UCI) Health - UC Irvine Me-Chao Family Comprehensive Cancer Cente

Orange, California, United States

Site Status

Karmanos Cancer Institute ( Site 1007)

Detroit, Michigan, United States

Site Status

Memorial Sloan Kettering - Basking Ridge ( Site 1023)

Basking Ridge, New Jersey, United States

Site Status

Memorial Sloan Kettering - Monmouth ( Site 1022)

Middletown, New Jersey, United States

Site Status

Memorial Sloan Kettering - Bergen ( Site 1025)

Montvale, New Jersey, United States

Site Status

Memorial Sloan Kettering- Commack ( Site 1021)

Commack, New York, United States

Site Status

Memorial Sloan Kettering - Westchester ( Site 1020)

Harrison, New York, United States

Site Status

Memorial Sloan Kettering Cancer Center ( Site 1002)

New York, New York, United States

Site Status

Memorial Sloan Kettering - Nassau ( Site 1026)

Uniondale, New York, United States

Site Status

Oklahoma Cancer Specialists and Research Institute, LLC ( Site 1024)

Tulsa, Oklahoma, United States

Site Status

Sanford Cancer Center-Gynecologic Oncology ( Site 1015)

Sioux Falls, South Dakota, United States

Site Status

Houston Methodist Hospital ( Site 1017)

Houston, Texas, United States

Site Status

Kingston Health Sciences Centre-Kingston General Hospital Site ( Site 1051)

Kingston, Ontario, Canada

Site Status

Princess Margaret Cancer Centre ( Site 1056)

Toronto, Ontario, Canada

Site Status

FALP-UIDO ( Site 1401)

Santiago, Region M. de Santiago, Chile

Site Status

Oncovida ( Site 1405)

Santiago, Region M. de Santiago, Chile

Site Status

Bradfordhill-Clinical Area ( Site 1402)

Santiago, Region M. de Santiago, Chile

Site Status

James Lind Centro de Investigacion del Cancer ( Site 1404)

Temuco, Región de la Araucanía, Chile

Site Status

Fundacion Colombiana de Cancerología Clinica Vida ( Site 1422)

Medellín, Antioquia, Colombia

Site Status

Clinica de la Costa S.A.S. ( Site 1421)

Barranquilla, Atlántico, Colombia

Site Status

Instituto Nacional de Cancerología-Clinical Oncology ( Site 1425)

Bogotá, Cundinamarca, Colombia

Site Status

Oncologos del Occidente ( Site 1424)

Pereira, Risaralda Department, Colombia

Site Status

Fundación Cardiovascular de Colombia ( Site 1423)

Piedecuesta, Santander Department, Colombia

Site Status

CENTRE LEON BERARD-Medical oncology ( Site 1151)

Lyon, Auvergne-Rhône-Alpes, France

Site Status

Centre Georges François Leclerc ( Site 1155)

Dijon, Cote-d Or, France

Site Status

Institut Regional du Cancer Montpellier ( Site 1157)

Montpellier, Herault, France

Site Status

Gustave Roussy-medicine departement ( Site 1153)

Villejuif, Paris, France

Site Status

Sainte Catherine Institut du Cancer Avignon Provence-Oncologie médicale ( Site 1156)

Avignon, Vaucluse, France

Site Status

Institut Curie ( Site 1152)

Paris, , France

Site Status

Universitaetsklinikum Heidelberg-Nationales Centrum für Tumorerkrankungen ( Site 1180)

Heidelberg, Baden-Wurttemberg, Germany

Site Status

Universitaetsklinikum Tuebingen-Department of Internal Medicine VIII - Medical Oncology, ECTU, Pne

Tübingen, Baden-Wurttemberg, Germany

Site Status

Klinikum der Universität München Großhadern ( Site 1176)

München, Bavaria, Germany

Site Status

Universitaetsklinikum Duesseldorf-Gastroenterology, Hepatology and Infectiology ( Site 1172)

Düsseldorf, North Rhine-Westphalia, Germany

Site Status

Charite Universitätsmedizin Berlin Campus Benjamin Franklin ( Site 1171)

Berlin, , Germany

Site Status

Rambam Health Care Campus-Oncology ( Site 1141)

Haifa, , Israel

Site Status

Hadassah Medical Center-Oncology ( Site 1142)

Jerusalem, , Israel

Site Status

Sheba Medical Center-ONCOLOGY ( Site 1144)

Ramat Gan, , Israel

Site Status

Sourasky Medical Center-Oncology ( Site 1143)

Tel Aviv, , Israel

Site Status

Fondazione Policlinico Universitario Agostino Gemelli IRCCS -Ginecologia Oncologica ( Site 1136)

Rome, Lazio, Italy

Site Status

Ospedale San Raffaele-Oncologia Medica ( Site 1135)

Milan, Lombardy, Italy

Site Status

Istituto Clinico Humanitas-U.O di Oncologia medica ed Ematologia ( Site 1138)

Rozzano, Milano, Italy

Site Status

Istituto Europeo di Oncologia IRCCS-Divisione di Sviluppo di Nuovi Farmaci per Terapie Innovative (

Milan, , Italy

Site Status

Istituto Nazionale Tumori IRCCS Fondazione Pascale-S.C. Sperimentazioni Cliniche ( Site 1134)

Napoli, , Italy

Site Status

Aichi Cancer Center Hospital ( Site 1324)

Nagoya, Aichi-ken, Japan

Site Status

National Cancer Center Hospital East ( Site 1321)

Kashiwa, Chiba, Japan

Site Status

Osaka International Cancer Institute ( Site 1323)

Osaka, , Japan

Site Status

National Cancer Center Hospital ( Site 1322)

Tokyo, , Japan

Site Status

Nederlands Kanker Instituut - Antoni van Leeuwenhoek - NKI-AVL ( Site 1121)

Amsterdam, North Holland, Netherlands

Site Status

Erasmus Medisch Centrum-Medical Oncology ( Site 1122)

Rotterdam, South Holland, Netherlands

Site Status

Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Oddzial Badan Wczesnych Faz ( Site 1101

Warsaw, Masovian Voivodeship, Poland

Site Status

Uniwersyteckie Centrum Kliniczne-Early Clinical Trials Unit ( Site 1103)

Gdansk, Pomeranian Voivodeship, Poland

Site Status

Szpital Wojewódzki im. Mikoaja Kopernika w Koszalinie-Oddzial Dzienny Chemioterapii ( Site 1104)

Koszalin, West Pomeranian Voivodeship, Poland

Site Status

Seoul National University Hospital-Internal Medicine ( Site 1312)

Seoul, , South Korea

Site Status

Severance Hospital, Yonsei University Health System-Medical oncology ( Site 1311)

Seoul, , South Korea

Site Status

Asan Medical Center ( Site 1313)

Seoul, , South Korea

Site Status

Instituto Catalan de Oncologia - Hospital Duran i Reynals-Medical Oncology ( Site 1113)

Hospitalet, Barcelona, Spain

Site Status

HOSPITAL UNIVERSITARIO QUIRONSALUD MADRID-ONCOLOGIA MEDICA ( Site 1117)

Pozuelo de Alarcón, Madrid, Spain

Site Status

Hospital Universitario Ramón y Cajal-Medical Oncology ( Site 1111)

Madrid, Madrid, Comunidad de, Spain

Site Status

Clinica Universidad de Navarra-Medical Oncology ( Site 1118)

Madrid, , Spain

Site Status

HOSPITAL UNIVERSITARIO VIRGEN DEL ROCIO ( Site 1114)

Seville, , Spain

Site Status

NATIONAL CHENG-KUNG UNI. HOSP.-clinical trial center ( Site 1302)

Tainan City, , Taiwan

Site Status

National Taiwan University Hospital-Oncology ( Site 1301)

Taipei, , Taiwan

Site Status

Mackay Memorial Hospital ( Site 1305)

Taipei, , Taiwan

Site Status

Chang Gung Medical Foundation-Linkou Branch ( Site 1304)

Taoyuan District, , Taiwan

Site Status

Istanbul Universitesi Cerrahpasa ( Site 1203)

Istanbul- Fatih, Istanbul, Turkey (Türkiye)

Site Status

Baskent University Dr. Turgut Noyan Research and Training Center ( Site 1201)

Adana, , Turkey (Türkiye)

Site Status

Hacettepe Universitesi-oncology hospital ( Site 1209)

Ankara, , Turkey (Türkiye)

Site Status

Ankara City Hospital-Medical Oncology ( Site 1202)

Ankara, , Turkey (Türkiye)

Site Status

Trakya University-Medical Oncology ( Site 1207)

Edirne, , Turkey (Türkiye)

Site Status

Acibadem Universitesi Atakent Hastanesi ( Site 1208)

Istanbul, , Turkey (Türkiye)

Site Status

TC Saglik Bakanligi Goztepe Prof. Dr. Suleyman Yalcin Sehir Hastanesi-oncology ( Site 1204)

Istanbul, , Turkey (Türkiye)

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Canada Chile Colombia France Germany Israel Italy Japan Netherlands Poland South Korea Spain Taiwan Turkey (Türkiye)

Related Links

Access external resources that provide additional context or updates about the study.

https://www.merckclinicaltrials.com/

Merck Clinical Trials Information

https://msd.trialsummaries.com/Study/StudyDetails?id=26136&tenant=MT_MSD_9011

Plain Language Summary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

MK-7684A-005

Identifier Type: OTHER

Identifier Source: secondary_id

jRCT2031210335

Identifier Type: REGISTRY

Identifier Source: secondary_id

KEYVIBE-005

Identifier Type: OTHER

Identifier Source: secondary_id

2023-505284-36-00

Identifier Type: REGISTRY

Identifier Source: secondary_id

U1111-1291-4290

Identifier Type: REGISTRY

Identifier Source: secondary_id

2021-001009-56

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

7684A-005

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005)
NCT03797326 COMPLETED PHASE2
Pembrolizumab and Monoclonal Antibody Therapy in Advanced Cancer
NCT02318901 TERMINATED PHASE1/PHASE2
Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
NCT04787042 RECRUITING PHASE1/PHASE2
A Study of Gebasaxturev (V937) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors (V937-013)
NCT04521621 TERMINATED PHASE1/PHASE2
Study of Quavonlimab (MK-1308) in Combination With Pembrolizumab (MK-3475) in Advanced Solid Tumors (MK-1308-001)
NCT03179436 COMPLETED PHASE1/PHASE2
A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies
NCT07223047 RECRUITING PHASE1/PHASE2
Pembrolizumab + Paclitaxel +/- Bevacizumab for Triple-negative Breast Cancer
NCT06976944 RECRUITING PHASE2
Testing the Combination of New Anti-cancer Drug Peposertib With Avelumab and Radiation Therapy for Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies
NCT04068194 SUSPENDED PHASE1/PHASE2
A Study of MK-6837 as a Monotherapy and Combination Therapy in Participants With Advanced/Metastatic Solid Tumors (MK-6837-001)
NCT06460961 ACTIVE_NOT_RECRUITING PHASE1
Safety and Efficacy Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy as Neoadjuvant Treatment for Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-173/KEYNOTE-173)
NCT02622074 COMPLETED PHASE1
Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522)
NCT03036488 COMPLETED PHASE3
Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) for Advanced Melanoma in Anti-Programmed Death-1/Programmed Death-Ligand 1 (PD-1/L1)-Exposed Participants (MK-7902-004/E7080-G000-225/LEAP-004)
NCT03776136 COMPLETED PHASE2
Study of Pembrolizumab (MK-3475) Monotherapy for Metastatic Triple-Negative Breast Cancer (MK-3475-086/KEYNOTE-086)
NCT02447003 COMPLETED PHASE2
A Study of BMS-986466 With Adagrasib With or Without Cetuximab in Participants With Kirsten Rat Sarcoma Virus Glycine 12 to Cysteine (KRAS G12C)-Mutant Solid Tumors
NCT06024174 TERMINATED PHASE1/PHASE2
Study of Boserolimab (MK-5890) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Adults With Advanced Solid Tumors (MK-5890-001)
NCT03396445 COMPLETED PHASE1
Study of Olaparib (MK-7339) in Combination With Pembrolizumab (MK-3475) in the Treatment of Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer (MK-7339-007/KEYLYNK-007)
NCT04123366 ACTIVE_NOT_RECRUITING PHASE2
A Clinical Trial Evaluating TQB2102 for Injection in Combination With Behmosubaisumab/Payamprolizumab With or Without Chemotherapy in Unresectable Locally Advanced, Recurrent, or Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastroesophageal Adenocarcinoma
NCT06767800 RECRUITING PHASE2
Study of First-line Pembrolizumab (MK-3475) With Lenvatinib (MK-7902/E7080) in Urothelial Carcinoma Cisplatin-ineligible Participants Whose Tumors Express Programmed Cell Death-Ligand 1 and in Participants Ineligible for Platinum-containing Chemotherapy (MK-7902-011/E7080-G000-317/ LEAP-011)
NCT03898180 COMPLETED PHASE3
Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)
NCT03725059 ACTIVE_NOT_RECRUITING PHASE3
Study of BMS-986315 Alone and in Combination With Nivolumab or Cetuximab in Participants With Advanced Solid Tumors
NCT04349267 COMPLETED PHASE1/PHASE2
A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors
NCT04725331 TERMINATED PHASE1/PHASE2
A Study to Test BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) and BI 765179 in Combination With Pembrolizumab in Patients With Advanced Head and Neck Cancer
NCT04958239 ACTIVE_NOT_RECRUITING PHASE1
A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors
NCT06697197 RECRUITING PHASE1/PHASE2
A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors
NCT04895709 RECRUITING PHASE1/PHASE2
Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies
NCT04913337 ACTIVE_NOT_RECRUITING PHASE1/PHASE2